Analysis of Factors Affecting Proteinuria Onset Timing in Patients Treated with Bevacizumab / ベバシズマブによるタンパク尿発現時期に関するリスク因子の検討
- Resource Type
- Journal Article
- Authors
- Atsushi Hirata; Aya Murakami; Keisuke Noto; Ryosuke Ota; 太田 涼介; 平田 敦士; 村上 綾; 能登 啓介
- Source
- YAKUGAKU ZASSHI. 2022, 142(6):641
- Subject
- bevacizumab
dose
onset time
proteinuria
- Language
- Japanese
- ISSN
- 0031-6903
1347-5231
Bevacizumab (BV) is a recombinant and humanized monoclonal antibody that inhibits vascular endothelial growth factor. BV is used to treat various types of cancer. Proteinuria is a characteristic adverse event that occurs as a result of treatment with BV. However, the onset timing of proteinuria after BV administration remains unclear. In the present study, we examined the risk factors affecting the timing of proteinuria onset upon BV administration. Medical records of 135 patients (62 males and 73 females; mean age: 67.8±10.7 years) treated with BV were reviewed at the Kindai University Nara Hospital from April 2011 to December 2019. Proteinuria was identified in 44.4% (60/135) of the studied patients. The time to the first onset of proteinuria was significantly shorter in the administration of doses of BV (≥10) and history of diabetes mellitus. The median cumulative dose associated with the onset of proteinuria was 30.0 (16.1-58.8) mg/kg. When this cumulative dose was compared with 10 mg/kg, no significant difference was observed (p=0.319). The present study demonstrated that the administration of doses of BV (≥10) and history of diabetes mellitus are one of the main risk factors for early-onset proteinuria. These findings may be useful for the future treatment of early-onset proteinuria in patients treated with BV.